Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Lilly And AC Immune Partner On A Small Molecule With Potential In Alzheimer's Combinations

Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.

Neurology Deals Research & Development

Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline

Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.

Rare Diseases Companies Leadership

City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement

City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.

ImmunoOncology Market Access Comparative Effectiveness
Advertisement


 Recent Tweets from Scrip


Clinical Trial Packaging: Innovative, Flexible and Time Sensitive Solutions

Clinical trial packaging can be diverse as the medications they protect. Experience gained across a broad range of studies can guide the design process towards a solution that meets the sponsor’s immediate and long term needs. Read more and learn about clinical study sponsor’s innovative, flexible and time sensitive solutions.

Read Now

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

 

Commercial Explore this Topic

Set Alert for Commercial

Asia Deal Watch: Takeda, Eisai Team With Non-Profit On Review Of Novel Targets For Antibiotics

The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.

Asia Pacific Deals Business Strategies

OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

The UK start-up has quickly switched from research services to drug discovery to exploit more fully its novel platform technology for drug screening and development, funded by Syncona and other investors.

 

StartUps and SMEs Platform Technologies Research & Development

After Imbruvica Passes Chemo-Free Tests, Shorter Duration Regimens Could Be Next Value-Adds

AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.

Research and Development Strategies Cancer

Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus

US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.

Biosimilars Metabolic Disorders

Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

Sanofi and Gilead moved down in the rankings of Scrip's top 100 pharmaceutical companies, based on 2017 pharma sales, while Johnson & Johnson, GSK and AbbVie moved up. Shire joined the top 20 just as it is about to be consumed by Takeda.

Commercial Business Strategies

Novo Nordisk CSO Outlines Obesity R&D Strategy, Calls Condition "Ticking Time Bomb"

Novo Nordisk' obesity pipeline consists of projects addressing both appetite reduction and energy expenditure, with GLP-1 semaglutide topping the list, its CSO says in an interview with Scrip.

Business Strategies Commercial

Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

Scrip's latest rankings of the top 100 revenue earners in the medical technology industry, published in Outlook 2019, show the groups leading the global market tightening their grip further in 2017. This was partly a function of providers choosing to partner more and more with fewer suppliers who can offer a wider provision of services. But it was steady as she goes for most of the multinational medtechs, with some major exceptions, and there will be more M&A reflected in next year's rankings, based on 2018 revenues.
Outlook 2019 Market Intelligence

The Harsh Light Of Hard Facts: Valuing Pharma In A Made For Measure World

With a challenging new decade of scientific discovery looming, 2019 is the positioning year for biopharma to make value, transparency, information and culture work seamlessly to achieve innovations that matter to patients, payers and society.

Commercial Market Intelligence

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Pilots Between NHS And Pharma Finally Take Off

The majority of pharmaceutical companies in the UK work closely with the NHS and In Vivo spoke to one of them – Janssen – to see how successful industry, health care providers and payers have been in breaking out of their silos and collaborating.

United Kingdom Commercial Market Access

Brexit And Cooperation: Insights From Danish Medicines Agency Head Thomas Senderovitz

It was inevitable that Brexit would be the key theme of an interview with Danish Medicines Agency head Thomas Senderovitz earlier this year. The senior European regulator oversees one of the agencies that has taken on new staff to help deal with the impact, in drug regulatory terms, of the vote by the UK in June 2016 to leave the European Union. Senderovitz also chairs the management group of the EU Heads of Medicines Agencies network.

Leadership Outlook 2019

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.

Approvals ImmunoOncology

Pharma: Be Prepared For Tougher Price Negotiations For IO Combos And Expansions In Europe

Payers are increasingly likely to implement new strategies to manage price negotiations for immuno-oncology combinations, as competition  heats up among the drug class. Mechanisms allowing for the negotiation of different prices for combination therapies do not exist at present, but payers insist that new tools must emerge.

ImmunoOncology Health Technology Assessment

Research & Development Explore this Topic

Set Alert for Research & Development

ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance

Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.

Valbenazine's Consistent But Weak Effect In Tourette Dismays Neurocrine

In "very top-line" Phase IIb data, the magnitude of the treatment effect for valbenazine in children with Tourette syndrome was weaker than expected, and its loss from active development means there will be only a handful of candidates under evaluation for the disorder.

Clinical Trials Neurology

Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.

Companies Research & Development

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Research and Development Strategies Research & Development
UsernamePublicRestriction

Register

Advertisement